Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation StrategySupplement Articles Published on 2021-12-052022-10-29 Journal: Journal of the Canadian Association of Gastroenterology [Category] COVID-19, [키워드] Canada Community Consensus coronavirus Course COVID-19 Critical Crohn’s disease Crohn’s disease global pandemic Guidance IBD Immunocompromised Impact impacted individual Inflammatory bowel disease information International knowledge lockdown management medications mental health pandemic physical distancing platform Prevalence provided public health recommendation resource risk stratification SARS-CoV-2 second wave Strategy translation ulcerative colitis unique website World Health Organization’ [DOI] 10.1093/jcag/gwab028 PMC 바로가기 [Article Type] Supplement Articles
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBDSupplement Articles Published on 2021-12-052022-10-29 Journal: Journal of the Canadian Association of Gastroenterology [Category] COVID-19, [키워드] acute respiratory distress age aging Care Chronic illness Comorbidity coronavirus COVID-19 Crohn’s disease database death decrease elderly ENhance expressed extreme General population Health healthcare Hospitalization IBD immune response immune system Impact increase increased risk Inflammatory bowel disease Inflammatory response Influenza information Italy less morbidity and mortality MOST organism Pneumonia reported resources respiratory responses risk robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV2 Satisfaction senescence severe COVID-19 shown syndrome turn ulcerative colitis vaccination Vaccinations while Youth [DOI] 10.1093/jcag/gwab025 PMC 바로가기 [Article Type] Supplement Articles
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and RecommendationsSupplement Articles Published on 2021-12-052022-10-29 Journal: Journal of the Canadian Association of Gastroenterology [Category] COVID-19, [키워드] adverse event anti-TNF approved Canada Chronic diseases Complete COVID-19 COVID-19 infection COVID-19 pandemic Crohn’s disease current death Efficacy Evidence first dose General population groups IBD immune response Immune-mediated Immunosuppressant Impact individual Inflammatory bowel disease International methotrexate National produced receive receiving reducing Regulatory robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines second dose shown symptomatic the vaccine therapy These data Trial ulcerative colitis vaccination Vaccine Vaccine development Vaccines were excluded [DOI] 10.1093/jcag/gwab033 PMC 바로가기 [Article Type] Supplement Articles
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Epidemiology—The Trends of Disease Over TimeSupplement Articles Published on 2021-12-052022-10-29 Journal: Journal of the Canadian Association of Gastroenterology [Category] COVID-19, [키워드] acute respiratory syndrome affecting Canada Canadian coronavirus coronavirus disease COVID-19 COVID-19 pandemic Crohn’s disease effective Epidemiology example General population IBD Immunity Immunocompromised Impact increased risk Inflammatory bowel disease Intervention medication over pandemic public health Region Reproduction number reproductive Research severe COVID-19 severe disease course Spread time Transmission trend ulcerative colitis vaccination variants of concern vector virus [DOI] 10.1093/jcag/gwab029 PMC 바로가기 [Article Type] Supplement Articles
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive SummarySupplement Articles Published on 2021-12-052022-10-29 Journal: Journal of the Canadian Association of Gastroenterology [Category] COVID-19, [키워드] Adults Canada Canadian children Community coronavirus COVID-19 COVID-19 pandemic Crohn’s disease delivery entire spectrum executive Factor Future group Health status health system higher risk highlight IBD immunosuppressive therapies Impact individual infected with SARS-CoV-2 Inflammatory bowel disease information knowledge literature review Mental Model online tool Person physical Physicians platform pregnant provide researchers SARS-CoV-2 severe disease course translation ulcerative colitis [DOI] 10.1093/jcag/gwab027 PMC 바로가기 [Article Type] Supplement Articles
Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease on Biological Agents During the SARS-CoV-2 PandemicObservational Study Published on 2021-12-012022-10-05 Journal: Digestive diseases and sciences [Category] 임상, [키워드] adherence adopted agent Biological Biologicals bowel Care clinical Clinical outcome Cohort collected combination therapy confirmed COVID-19 case COVID COVID-19 COVID19 cumulative drugs fear FIVE global pandemic hospital hospitals IBD immunosuppressants incidence Inflammatory bowel disease intravenous intravenous infusion measure Mild outbreak pandemic participated Patient perceptions performed Registered severity single-center the patient the SARS-CoV-2 therapy treated Treatment withdrawn [DOI] 10.1007/s10620-020-06807-0 PMC 바로가기 [Article Type] Observational Study
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD studyObservational Study Published on 2021-12-012022-10-05 Journal: Alimentary pharmacology & therapeutics [Category] SARS, 임상, [키워드] Active disease adverse outcome adverse outcomes age anti-TNF Asymptomatic build cohort study Comorbidity Course COVID-19 COVID-19 in patient death disease evaluated General population greater help higher risk hospitalisation IBD identify Immune-mediated Inflammatory bowel disease inflammatory disease lower risk medication moderate multivariable analyses multivariable logistic regression obesity outcome outcomes Patient patients Pneumonia risk risk factor Risk factors SARS-CoV-2 SARS-COV-2 infection severe COVID-19 significantly therapy ulcerative colitis ventilatory support was used [DOI] 10.1111/apt.16663 PMC 바로가기 [Article Type] Observational Study
Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel DiseaseResearch Article Published on 2021-11-302022-11-01 Journal: Canadian journal of gastroenterology & hepatology [Category] COVID-19, MERS, SARS, [키워드] age analyzed Biologic therapy Biomarkers Canada clinical clinical activity Cohort Comorbidities Comorbidity COVID-19 COVID-19 in patient COVID-19 infection COVID-19 vaccination COVID-19 vaccinations death diagnosed with COVID-19 died disease evaluate Factor female General population Hospitalization IBD immunosuppressive Impact increased risk Infection Inflammatory bowel disease initial IQR McGill University median Mortality occurred Odds ratio outcome outcomes Patient patients Pneumonia Prevalence prevalence of COVID-19 proportion reported Result risk factor severe COVID-19 Severe COVID-19 Infection significantly lower systemic corticosteroid therapy was obtained [DOI] 10.1155/2021/7591141 PMC 바로가기 [Article Type] Research Article
Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD TreatmentReview Published on 2021-11-302022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] Affect approved biologic clinical development Compliance Crohn’s disease cytokine Effectiveness Efficacy Future IBD immune pathways immunothrombosis implicated IMPROVE Inflammatory bowel disease inhibiting inhibitors Jak JAK inhibitor jak inhibitors Janus kinase medical need monoclonal antibodies pandemic Pathogenesis patients patients with COVID-19 question risk Safety safety profile several limitations Signaling small molecule Small molecules susceptibility the SARS-CoV-2 therapeutic response therapy Thromboembolic events thrombotic complication Treatment treatment strategy ulcerative colitis [DOI] 10.3390/jcm10235660 PMC 바로가기 [Article Type] Review
Long COVID in Inflammatory Bowel DiseasesCommunication Published on 2021-11-262022-10-30 Journal: Journal of Clinical Medicine [Category] COVID-19, [키워드] acute infection appear biologics Course COVID COVID-19 infection Crohn’s disease defined demographic characteristics evaluated females Frequency IBD individual Inflammatory bowel disease investigated Long long-lasting not differ occurred Pathologies Patient patients public health Quality of life recruited Rome SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-infected patient Symptom the patient two groups ulcerative colitis university [DOI] 10.3390/jcm10235575 PMC 바로가기 [Article Type] Communication